{
    "clinical_study": {
        "@rank": "66956", 
        "acronym": "OptiHER-Heart", 
        "arm_group": {
            "arm_group_label": "Liposomal Doxorubicin", 
            "arm_group_type": "Experimental", 
            "description": "Six cycles of:\nTrastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks\nPertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks\nLiposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks\nPaclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of\n      neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients\n      with HER2-positive breast cancer"
        }, 
        "brief_title": "Study of Neoadjuvant Myocet\u00ae, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent for all study procedures according to local regulatory\n             requirements prior to beginning specific protocol procedures\n\n          -  Female patients\n\n          -  Age 18-74 years\n\n          -  ECOG Performance Status of 0 or 1\n\n          -  Histologically confirmed, untreated, invasive breast carcinoma stage II-IIIB\n\n          -  Tumor size > 2 cm by clinical or radiological assessment\n\n          -  HER2+ invasive BC according to ASCO/CAP guidelines\n\n          -  Known hormone receptor status or the possibility of its assessment\n\n          -  Adequate organ function defined as:\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1.5 x 10**9/L\n\n               -  Hemoglobin (Hgb) \u2265 9 g/dL\n\n               -  Platelets > 100 x 10**9/L\n\n               -  Creatinine \u2264 1.6 mg/dL\n\n               -  ALT and AST \u2264 2.5 x ULN\n\n               -  Alkaline phosphatase \u2264 5 ULN\n\n               -  Total bilirubin \u2264 1.5 mg/dL\n\n          -  Baseline LVEF \u2265 55% measured by echocardiogram or MUGA scan\n\n          -  Negative \u03b2-HCG pregnancy test (serum) for premenopausal women of reproductive\n             capacity (those who are biologically capable of having children) and for women less\n             than 12 months after the menopause. All subjects who are biologically capable of\n             having children must agree and commit to the use of a reliable method of birth\n             control from 2 weeks before administration of the first dose of investigational\n             product until 28 days after the last dose of investigational product\n\n          -  Absence of any psychological, familial, sociological, or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule;\n             those conditions should be discussed with the patient before registration in the\n             trial\n\n        Exclusion Criteria:\n\n          -  Clinical or radiologic evidence of metastatic disease at the time of study entry\n\n          -  Prior chemotherapy, radiotherapy, or surgery for BC, other than excision of a tumor\n             in the contralateral breast, and provided that the patient did not previously receive\n             adjuvant radiotherapy or chemotherapy\n\n          -  Subjects with a concurrently active second malignancy, other than adequately treated\n             non melanoma skin cancers, in situ melanoma or in situ cervical cancer. Subjects with\n             other non-mammary malignancies must have been disease-free for at least 5 years\n\n          -  Known or suspected hypersensitivity reaction to any investigational or therapeutic\n             compound or their incorporated substances\n\n          -  Presence of CHF or LVEF < 55%\n\n          -  Clinically significant (i.e. active) cardiovascular disease, including\n             cerebrovascular accident (< 6 months before enrollment), unstable angina pectoris,\n             myocardial infarction \u2264 6 months before enrollment, uncontrolled hypertension\n             (systolic > 150 mmHg and/or diastolic > 100 mmHg), or high-risk uncontrolled\n             arrhythmias\n\n          -  Uncontrolled diabetes mellitus, active peptic ulcer disease, or uncontrolled epilepsy\n\n          -  Active uncontrolled infection at the time of enrolment\n\n          -  History of significant co-morbidities that, in the judgment of the investigator, may\n             interfere with the conduction of the study, the evaluation of response, or with\n             informed consent\n\n          -  Use of any investigational agent or participation in another therapeutic clinical\n             trial concurrently or in the previous 30 days before the enrollment\n\n          -  Patients who are pregnant or breast-feeding\n\n          -  Women of child-bearing potential who are unable or unwilling to use acceptable\n             contraceptive measures\n\n          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the\n             investigator or designee"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669239", 
            "org_study_id": "SOLTI-1002", 
            "secondary_id": "2012-001201-24"
        }, 
        "intervention": {
            "arm_group_label": "Liposomal Doxorubicin", 
            "description": "Six cycles of:\nTrastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks\nPertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks\nLiposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks\nPaclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks", 
            "intervention_name": "Liposomal Doxorubicin", 
            "intervention_type": "Drug", 
            "other_name": "Myocet\u00ae (liposome-encapsulated doxorubicin)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Trastuzumab", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "HER2 positive", 
            "Neoadjuvant", 
            "Liposomal doxorubicin", 
            "Paclitaxel", 
            "Trastuzumab", 
            "Pertuzumab", 
            "Safety"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "link": {
            "description": "SOLTI Breast Cancer Research Group", 
            "url": "http://www.gruposolti.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Vall d\u00b4Hebron"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednic de Barcelona"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00e1ceres", 
                        "country": "Spain"
                    }, 
                    "name": "Complejo Hospitalario San Pedro de Alc\u00e1ntara"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari Arnau de Vilanova de Lleida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Puerta de Hierro de Majadahonda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Cl\u00ednico San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Ramon y Cajal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Centro Integral Oncol\u00f3gico Clara Campal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "MD Anderson Cancer Center Madrid"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Virgen de la Arrixaca"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Son Ll\u00e0tzer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari Son Espases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reus", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Sant Joan de Reus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Virgen de la Macarena"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Virgen del Roc\u00edo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Sagrado Coraz\u00f3n USP"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Arnau de Vilanova de Valencia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario Lozano Blesa"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet\u00ae) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer", 
        "overall_official": {
            "affiliation": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda", 
            "last_name": "Joaqu\u00edn Gavil\u00e1 Gregori, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period", 
            "safety_issue": "Yes", 
            "time_frame": "Following 12 months after first dose of the study treatment"
        }, 
        "reference": {
            "citation": "Gavil\u00e1 J, Llombart A, Guerrero A, Ru\u00edz A, Climent M, Guillem V. Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer. Poster session presented at: 35th Annual San Antonio Breast Cancer Symposium (SABCS); 2012 December 4th-8th; San Antonio, Texas, United States."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "pCR in breast (pCRB)", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery, an expected average of 23 weeks"
            }, 
            {
                "measure": "pCR in breast and axilla (pCRBA)", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery, an expected average of 23 weeks"
            }, 
            {
                "measure": "Clinical  objective  response  rate  (cORR)  in  the  breast  and  axilla  by  RECIST  criteria version 1.1", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery, an expected average of 23 weeks"
            }, 
            {
                "measure": "Residual Cancer Burden (RCB) at surgery following the procedures of the MD Anderson Cancer Center", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery, an expected average of 23 weeks"
            }, 
            {
                "measure": "Breast conservation rate at surgery", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery, an expected average of 23 weeks"
            }, 
            {
                "measure": "Evaluation of serum biomarkers predictive of cardiotoxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }, 
            {
                "measure": "Percentage of patients with grade 3/4 neutropenia (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }, 
            {
                "measure": "Time of onset and time of recovery from symptomatic (type A) and asymptomatic (type B) cardiac events (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }, 
            {
                "measure": "Dose reductions due to treatment toxicity (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }, 
            {
                "measure": "Dose delays due to treatment toxicity (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }, 
            {
                "measure": "Number of patients with adverse events and serious adverse events (assessed by CTCAE v.4)", 
                "safety_issue": "Yes", 
                "time_frame": "Following 12 months after first dose of the study treatment"
            }
        ], 
        "source": "SOLTI Breast Cancer Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SOLTI Breast Cancer Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}